This case was reported in a literature article and described the occurrence of vaccination failure in a adult subject who received Meningococcal B Recom vaccine + AlOH + OMV for prophylaxis. On an unknown date, unknown after receiving Meningococcal B Recom vaccine + AlOH + OMV, the subject developed vaccination failure. Serious criteria included GSK medically significant. Additional event(s) included meningococcal infection with serious criteria of GSK medically significant. The outcome of vaccination failure was unknown. The outcome(s) of the additional event(s) included meningococcal infection (unknown). The investigator considered that there was a reasonable possibility that the vaccination failure and meningococcal infection may have been caused by Meningococcal B Recom vaccine + AlOH + OMV. Relevant Tests: Lab test performed on unspecified date between 1 January 2014 and 31 December 2016, the patient developed meningococcal disease (serotype unknown). Additional information was provided. This case was reported in a literature article and described the suspected vaccination failure in a patient aged between 18 and 24 of unspecified gender who was vaccinated with unspecified meningococcal B vaccine (manufacturer unknown) for prophylaxis. The patient was a part of the study that described the epidemiology of meningococcal disease in college students, estimated the relative risk (RR) of meningococcal disease in college students compared with non-college students among persons aged 18 to 24 years and characterized the disease-causing strains. The patient was among the college students. No information on patient's family or medical history or concurrent condition or concomitant medication was provided. On an unspecified date, the patient received equal to or more than 1 dose of unspecified meningococcal B vaccine (administration route and site unspecified; dosages unknown; batch number not provided). Age of vaccination was not provided. On an unspecified date between 1 January 2014 and 31 December 2016, an unknown period after vaccination, the patient developed meningococcal disease (serotype unknown). This case has been considered as suspected vaccination failure being full schedule/time to onset and laboratory confirmation of serotype was unknown. This case has been considered serious due to suspected vaccination failure. The author did not comment on the relationship between the event of meningococcal disease and unspecified meningococcal B vaccine. The author concluded, "Although the incidence is low, college students are at an increased risk for sporadic and outbreak-associated MenB disease compared with noncollege students. Providers, college students, and parents should be aware of the availability of MenB vaccines. Additionally, with growing evidence of the impact of MenACWY vaccines on meningococcal disease in adolescents, all adolescents should receive this vaccine according to ACIP recommendations regardless of college attendance. Finally, continued surveillance for meningococcal disease will be critical for monitoring the epidemiology of meningococcal disease in college students and informing public health prevention and response strategies." Lab Comments: Lab test performed on unspecified date between 1 January 2014 and 31 December 2016, the patient developed meningococcal disease (serotype unknown).